 |
February 2, 2010
Vol. XXVII, No. 6
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
Safety & Efficacy of Clopidogrel by Gender |
|
New data demonstrate that clopidogrel reduces the risk of cardiovascular (CV) events in both women and men. The study found that clopidogrel was associated with a highly significant 14% proportional reduction in the risk of CV events with no significant differences in treatment effect between women and men. In women, the risk reduction with clopidogrel seemed to be greatest for myocardial infarction (MI); effects on stroke and total death were not statistically significant. Among men, the risk reduction was significant for MI, stroke, and total death.
Source: Journal of the American College of Cardiology, November 17, 2009.
|
|
REFERENCE LINKS:
|
An abstract of the study is available at
|
|
|
|
|
| To get Physician's Weekly posted in your hospital, click HERE |
|
|
|
| |
